- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06269133
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
March 11, 2024 updated by: Regeneron Pharmaceuticals
Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity.
Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients and baseline variables will be captured retrospectively, but outcome measures will be prospectively ascertained.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Study Locations
-
-
New York
-
Tarrytown, New York, United States, 10591
- Regeneron Research Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with advanced disease, defined as stage IIIB, IIIC, or IV disease, with evidence of administration of 1L cemiplimab in combination with platinum-doublet chemotherapy between 08 Nov 2022 and 30 Jun 2026 and without EGFR, ALK, and ROS1 genomic variants.
Description
Key Inclusion Criteria:
1. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol
Key Exclusion Criteria:
1. Patients who have EGFR, ALK or ROS1 variants
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study Patients
Patients who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.
|
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Other Names:
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Real-world response rate (rwRR)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Any treatment-emergent immune-mediated adverse event (imAE)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Any treatment-emergent imAE resulting in hospitalization
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Any treatment-emergent imAE resulting in death
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Specific treatment-emergent imAEs
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Real-world duration of response (rwDOR)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Real-world progression-free survival (rwPFS)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Real-world overall survival (rwOS)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Treatment-emergent immune-mediated adverse events (imAEs)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Infusion-related reaction (IRR)
Time Frame: Approximately 3 years
|
Approximately 3 years
|
IRR resulting in hospitalization
Time Frame: Approximately 3 years
|
Approximately 3 years
|
IRR resulting in death
Time Frame: Approximately 3 years
|
Approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 21, 2024
Primary Completion (Estimated)
March 31, 2027
Study Completion (Estimated)
June 23, 2027
Study Registration Dates
First Submitted
February 13, 2024
First Submitted That Met QC Criteria
February 13, 2024
First Posted (Actual)
February 21, 2024
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R2810-ONC-22115
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
-
Gilead SciencesArcus Biosciences, Inc.RecruitingLung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung CancerUnited States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Clinical Trials on REGN2810
-
Regeneron PharmaceuticalsSanofiTerminatedNon-small Cell Lung CancerUnited States, Italy, Lithuania
-
Regeneron PharmaceuticalsSanofiActive, not recruitingNon-small Cell Lung CancerUnited States, France, Korea, Republic of, Italy, Austria, China, Georgia, Greece, Ireland, Lithuania, Malaysia, Poland, Romania, Russian Federation, Slovakia, Thailand, Turkey, Ukraine
-
National Institute of Allergy and Infectious Diseases...Regeneron PharmaceuticalsTerminated
-
Regeneron PharmaceuticalsTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Regeneron PharmaceuticalsSanofiActive, not recruitingCutaneous Squamous Cell CarcinomaUnited States, Germany, Australia
-
Regeneron PharmaceuticalsSanofiNo longer availableCutaneous Squamous Cell Carcinoma
-
Regeneron PharmaceuticalsRecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)United States
-
Regeneron PharmaceuticalsSanofiRecruitingBasal Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Regeneron PharmaceuticalsBioNTech SERecruitingAdvanced Non-Small Cell Lung CancerUnited States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey